# Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

> **NCT00573131** · PHASE2 · TERMINATED · sponsor: **Boston Scientific Corporation** · enrollment: 137 (actual)

## Conditions studied

- Esophageal Cancer
- Adenocarcinoma of the Esophagus
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** OncoGel (Paclitaxel gel)
- **DRUG:** cisplatin
- **DRUG:** 5-FU
- **RADIATION:** radiation therapy
- **PROCEDURE:** esophageal resection

## Key facts

- **NCT ID:** NCT00573131
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 137 (ACTUAL)
- **Why stopped:** OncoGel did not show any impact on overall tumor response
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00573131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00573131, "Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00573131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*